| Literature DB >> 28316688 |
S Kadkhodayan1, F Homaee Shandiz2.
Abstract
Introduction: The most common cancer is Breast Cancer and the first principal purpose of cancer deaths in females of 44-40 ages. The currency of three negative breast cancer involves 10-17%. his sort cancer of the breast is described by a negative receptor of estrogen, progesterone, and HER2 that is much more competitive than the other kinds and the forecast is weaker. Therefore, this research was conducted with the aim of evaluating the outcomes of the medication in patients with a triple negative sort of breast cancer about the different patients with breast cancer. Method: This historical group research was conducted by leading to the reports of all patients with breast cancer whose medication and follow-up was conducted in Hospital of Mashhad Ghaem through 2001 and 2010, their ER, PR, HER2 outcomes being reported in the files. Based on immunohistochemical records (ER, PR, HER2), patients were split into 2 collections: triple negative and another negative and the therapeutic results were analyzed among the 2 groups regarding two and five-year disease-free and throughout durability by Kaplan-Meier method. P<0.05 was regarded necessary.Entities:
Keywords: Triple negative; cancer of breast; disease free survival; overall survival
Year: 2015 PMID: 28316688 PMCID: PMC5348930
Source DB: PubMed Journal: J Med Life ISSN: 1844-122X
Comparison of the overall survival among Triple negative and another negative groups
| Variables | Groups | P-value | ||
| Non TN | TN | |||
| Mean overall survival | 22.36 ±29.67 | 32.48 ± 24.1 | 0.306 | |
| Median of survival | 22.5 | 27 | ||
| Overall survival (%) | 1 year | 99 | 96.7 | |
| 2 years | 91.2 | 92.6 | ||
| 5 years | 76.5 | 71 |
Comparison of the disease-free survival in the Triple negative and non-Triple negative groups
| Variables | Groups | P-value | ||
| Non TN | TN | |||
| Mean disease-free survival | 28.21 ± 21.72 | 30.57 ± 24.56 | 0.184 | |
| Median of survival | 21 | 20 | ||
| Disease-free survival (%) | 1 year | 95.9 | 92.4 | |
| 2 years | 89.9 | 79.8 | ||
| 5 years | 73.3 | 66.7 |
Results of Cox regression to assess the simultaneous effect of variables on the disease-free survival
| Variables | Confidence interval 95% | Risk ratio | Model coefficient | P-value |
| Stage 1 | - | 1ª | - | 0.620 |
| Stage 2 | (0.113, 8.672) | 0.988 | -0.012 | 0.992 |
| Stage 3 | (0.020, 5.811) | 0.343 | -1.070 | 0.459 |
| Age | (0.394, 5.618) | 1.488 | 0.397 | 0.558 |
| Grade 1 | - | 1ª | - | 0.996 |
| Grade 2 | (0.000,-) | 0.000 | -12.218 | 0.979 |
| Grade 3 | (0.291,3.828) | 1.055 | 0.054 | 0.935 |
| a=reference group |
Results of Cox regression to assess the simultaneous effect of variables on the overall survival
| Variables | Confidence interval 95% | Risk ratio | Model coefficient | P-value |
| Stage 1 | - | 1ª | - | 0.804 |
| Stage 2 | (0.167, 11.151) | 1.363 | 0.310 | 0.773 |
| Stage 3 | (0.067, 9.547) | 0.797 | -0.227 | 0.858 |
| Age | (0.266, 3.761) | 1.000 | 0.000 | 1.000 |
| Grade 1 | - | 1ª | - | 0.900 |
| Grade 2 | (0.000,-) | 0.000 | -12.398 | 0.979 |
| Grade 3 | (0.216, 2.594) | 0.748 | -0.290 | 0.647 |
| a=reference group |